Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Metrics to compare | 1RV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1RVPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −2.4x | −0.6x | |
PEG Ratio | 0.00 | −0.06 | 0.00 | |
Price/Book | 0.0x | 2.5x | 2.6x | |
Price / LTM Sales | 0.0x | 12.8x | 3.2x | |
Upside (Analyst Target) | 0.0% | 209.0% | 49.1% | |
Fair Value Upside | Unlock | 18.2% | 7.2% | Unlock |